SuperworthCaribou Biosciences revenue CRBU
Sales by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- $10M
- Latest quarter, Q2 FY26
- $1.5M
- −44% on a year earlier
- Fiscal year 2025
- $11.2M
- +12% on the year before
Caribou Biosciences' revenue was $10M over the twelve months to Jun 30, 2026, up 10% on a year earlier.
In its latest quarter, Q2 FY26, it was $1.5M, down 44% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 2% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $11.2M | +12% |
| FY2024 | $10M | −71% |
| FY2023 | $34.5M | +149% |
| FY2022 | $13.9M | +44% |
| FY2021 | $9.6M | −22% |
| FY2020 | $12.4M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.5M | −44% | $10M | |
| Q1 FY26 | $2.4M | +2% | $11.2M | |
| Q4 FY25 | $3.9M | +90% | $11.2M | |
| Q3 FY25 | $2.2M | +9% | $9.3M | |
| Q2 FY25 | $2.7M | −23% | $9.1M | |
| Q1 FY25 | $2.4M | −3% | $9.9M | |
| Q4 FY24 | $2.1M | −42% | $10M | |
| Q3 FY24 | $2M | −91% | $11.5M | |
| Q2 FY24 | $3.5M | −8% | $33.1M | |
| Q1 FY24 | $2.4M | −31% | $33.4M | |
| Q4 FY23 | $3.6M | −4% | $34.5M | |
| Q3 FY23 | $23.7M | +616% | $34.6M |
Against its peers
Companies in Healthcare nearest Caribou Biosciences' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| CRBUCaribou Biosciences | $10M | +10% a year |
| APTAlpha Pro Tech | $61.9M | +6% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| LFVNLifevantage | $182.6M | −20% a year |
| NEPHNephros | $20.7M | +24% a year |
| ICCCImmucell | $30.7M | +8% a year |
| KEQUKewaunee Scientific | $277.2M | +5% a year |
| PDEXPro DEX | $77.5M | +16% a year |
| PLXProtalix BioTherapeutics | $80.6M | +30% a year |
| NATRNatures Sunshine Products | $492M | +7% a year |
| Peer median | $77.5M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Caribou Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.